Walmart slides on slower U.S. sales amid Medicaid-driven drug-price shifts
Walmart’s stock dropped about 7% after the retailer reported 2.6% year-over-year U.S. comparable sales growth (excluding fuel) in the quarter, its weakest in years, as pharmacy pressure from changes to Medicare drug-price regulations weighed on results. Revenue rose to $187.9 billion, topping estimates, and Walmart raised its full-year sales guidance to 4%-5%. Analysts highlighted strength in e-commerce, advertising, and other value drivers, even as U.S. pharmacy headwinds linger.